Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli Lilly’s (LLY) Zepbound to its platform. The firm does ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic ...

green up pointing triangle & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.

The company said Tuesday it now provides access to Zepbound, a brand-name version of the drug tirzepatide, as well as to generic liraglutide. Zepbound is made by drugmaker Eli Lilly. While Hims ...

Wegovy and Zepbound both cost roughly $1,000 before insurance and other rebates. Allowing Medicare to cover those drugs and other weight loss medications could cost $35 billion over nine years ...